- Home
- HLP vs CGEN Comparison
HLP vs CGEN Comparison
Compare HLP & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLP
- CGEN
- Stock Information
- Founded
- HLP 2021
- CGEN 1993
- Country
- HLP China
- CGEN Israel
- Employees
- HLP N/A
- CGEN N/A
- Industry
- HLP Industrial Machinery/Components
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HLP Industrials
- CGEN Health Care
- Exchange
- HLP Nasdaq
- CGEN Nasdaq
- Market Cap
- HLP 110.2M
- CGEN 117.8M
- IPO Year
- HLP 2023
- CGEN 2000
- Fundamental
- Price
- HLP $1.00
- CGEN $1.51
- Analyst Decision
- HLP
- CGEN Strong Buy
- Analyst Count
- HLP 0
- CGEN 1
- Target Price
- HLP N/A
- CGEN $4.00
- AVG Volume (30 Days)
- HLP 117.3K
- CGEN 216.5K
- Earning Date
- HLP 06-19-2025
- CGEN 05-19-2025
- Dividend Yield
- HLP N/A
- CGEN N/A
- EPS Growth
- HLP N/A
- CGEN N/A
- EPS
- HLP N/A
- CGEN N/A
- Revenue
- HLP $14,105,620.00
- CGEN $27,589,000.00
- Revenue This Year
- HLP N/A
- CGEN $11.81
- Revenue Next Year
- HLP N/A
- CGEN $28.37
- P/E Ratio
- HLP N/A
- CGEN N/A
- Revenue Growth
- HLP N/A
- CGEN N/A
- 52 Week Low
- HLP $0.72
- CGEN $1.13
- 52 Week High
- HLP $2.25
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- HLP 40.21
- CGEN 56.16
- Support Level
- HLP $0.87
- CGEN $1.38
- Resistance Level
- HLP $1.01
- CGEN $1.56
- Average True Range (ATR)
- HLP 0.15
- CGEN 0.08
- MACD
- HLP -0.05
- CGEN 0.02
- Stochastic Oscillator
- HLP 21.05
- CGEN 77.74
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll formed steel profile manufacturer in China. It customizes and manufactures cold roll formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture and transportation.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.